Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 6, 2012, Pages 1022-1026

  Sprowl, J A ^a   Gregorc, V ^b   Lazzari, C ^b   Mathijssen, R H ^c   Loos, W J ^c   Sparreboom, A ^a,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXICITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; URINARY EXCRETION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; COHORT STUDIES; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC VARIATION; HUMANS; KIDNEY DISEASES; MICE; MICE, KNOCKOUT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RNA; WHOLE BODY IMAGING;

EID: 84861345636     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.330     Document Type: Article

References (30)

1. Chabner, B.A. & Longo, D.L. Cancer Chemotherapy and Biotherapy: Principles and Practice 5th edn. (Lippincott Williams & Wilkins, Philadelphia, PA, 2011).
2. de Jongh, F.E. et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J. Clin. Oncol. 19, 3733-3739 (2001). (Pubitemid 32844785)
3. Schellens, J.H. et al. Relationship between the exposure to cisplatin, DNAadduct formation in leucocytes and tumour response in patients with solid tumours. Br. J. Cancer 73, 1569-1575 (1996). (Pubitemid 26235386)
4. Schellens, J.H. et al. Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer. Br. J. Cancer 88, 814-821 (2003). (Pubitemid 36520865)
5. de Jongh, F.E., Gallo, J.M., Shen, M., Verweij, J. & Sparreboom, A. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother. Pharmacol. 54, 105-112 (2004). (Pubitemid 39044238)
6. Taniguchi, K. et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56, 4124-4129 (1996). (Pubitemid 26305002)
7. van Aubel, R.A., Smeets, P.H., Peters, J.G., Bindels, R.J. & Russel, F.G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol. 13, 595-603 (2002). (Pubitemid 34183923)
8. Kig, J., Nies, A.T., Cui, Y., Leier, I. & Keppler, D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461, 377-394 (1999).
9. Cascorbi, I. & Haenisch, S. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol. Biol. 596, 95-121 (2010).
10. Rius, M., Nies, A.T., Hummel-Eisenbeiss, J., Jedlitschky, G. & Keppler, D. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38, 374-384 (2003). (Pubitemid 36919858)
11. Naesens, M., Kuypers, D.R., Verbeke, K. & Vanrenterghem, Y. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation 82, 1074-1084 (2006). (Pubitemid 44632124)
12. de Jong, F.A. et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther. 81, 42-49 (2007). (Pubitemid 46050866)
13. Chu, X.Y. et al. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J. Pharmacol. Exp. Ther. 317, 579-589 (2006).
14. Franke, R.M. et al. Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin. Pharmacol. Ther. 89, 693-701 (2011).
15. Wakamatsu, T., Nakahashi, Y., Hachimine, D., Seki, T. & Okazaki, K. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int. J. Oncol. 31, 1465-1472 (2007).
16. Han, J.Y. et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110, 138-147 (2007).
17. Sun, N. et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 65, 437-446 (2010).
18. Ufer, M. et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet. Genomics 19, 353-362 (2009).
19. Haenisch, S. et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 7, 56-65 (2007). (Pubitemid 46322080)
20. Haenisch, S., May, K., Wegner, D., Caliebe, A., Cascorbi, I. & Siegmund, W. Influence of genetic polymorphisms on intestinal expression and rifampicintype induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet. Genomics 18, 357-365 (2008). (Pubitemid 351367529)
21. Zhang, Y., Zhao, T., Li, W. & Vore, M. The 5′-untranslated region of multidrug resistance associated protein 2 (MRP2; ABCC2) regulates downstream open reading frame expression through translational regulation. Mol. Pharmacol. 77, 237-246 (2010).
22. Han, B.et al. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer 72, 238-243 (2011).
23. Meyer zu Schwabedissen, H.E.et al. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab. Dispos. 33, 896-904 (2005).
24. Huisman, M.T., Chhatta, A.A., van Tellingen, O., Beijnen, J.H. & Schinkel, A.H. MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int. J. Cancer 116, 824-829 (2005). (Pubitemid 41099717)
25. Filipski, K.K., Mathijssen, R.H., Mikkelsen, T.S., Schinkel, A.H. & Sparreboom, A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther. 86, 396-402 (2009).
26. Nakamura, T., Yonezawa, A., Hashimoto, S., Katsura, T. & Inui, K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol. 80, 1762-1767 (2010).
27. Lancaster, C.S. et al. Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin. Cancer Res. 16, 4789-4799 (2010).
28. Filipski, K.K., Loos, W.J., Verweij, J. & Sparreboom, A. Interaction of cisplatin with the human organic cation transporter 2. Clin. Cancer Res. 14, 3875-3880 (2008).
29. Gregorc, V. et al. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin. Pharmacol. Ther. 83, 477-484 (2008). (Pubitemid 351272637)
30. Baker, S.D. et al. Pharmacogenetic pathway analysis of docetaxel elimination. Clin. Pharmacol. Ther. 85, 155-163 (2009).